Molecular Imaging and Biology

, Volume 10, Issue 3, pp 131–137 | Cite as

Role of FDG-PET in the Clinical Management of Paraneoplastic Neurological Syndrome: Detection of the Underlying Malignancy and the Brain PET-MRI Correlates

  • Sandip Basu
  • Abass AlaviEmail author
Review Article


The role of 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography (FDG-PET) imaging in the clinical management of paraneoplastic neurological syndrome (PNS) is in evolution. The initial results are promising, and the potential of this modality in this setting has been demonstrated in the literature. In the setting of PNS, FDG-PET imaging can be of value from the following standpoints: (1) detection of the occult malignant focus and (2) objective assessment of the presence and extent of the functional abnormality in the brain and correlation of the imaging findings with the clinical features and disease activity. For this communication, we have not considered case reports described in the literature, while tabulating the results of the published studies. However, we have referred to important observations made in such reports. In part, this effort has been made because of the relative paucity of the existing literature on this issue. The studies investigating the role of FDG-PET imaging in detecting the sites of malignancy can be divided into two broad categories: (A) studies that incorporated FDG-PET at the initial work up of PNS along with other modalities and (B) studies where FDG-PET was applied after conventional modalities had failed to detect the offending malignancy. While majority of the studies have been of the second category, both categories have demonstrated the incremental role of FDG-PET in the detection of the primary cancer in this setting. Also, it is evident that serial studies at certain intervals should be carried out if the initial FDG-PET scan is negative. The literature describing the central nervous system findings with PET in PNS are primarily restricted to paraneoplastic limbic encephalitis (PLE) and paraneoplastic cerebellar degeneration (PCD). FDG-PET usually shows hypermetabolism in one or both temporal lobes in the setting of paraneoplastic limbic encephalitis, and the magnetic resonance imaging (MRI) findings correlate with the FDG-PET scan results in only a fraction of cases. The functional–anatomic discordance between PET and MRI in PLE needs to be examined further, which might open up new insights into the disease process and might generate further subgroups within this entity. Both modalities complement each other in PLE, and frequently, abnormalities noted on FDG-PET images can provide additional clinical information which is of great value in further patient management. In the setting of paraneoplastic cerebellar degeneration, FDG-PET generally reveals cerebellar hypometabolism similar to the cerebellar atrophy demonstrated by MRI, and FDG-PET tends to show the abnormality more often than MRI.

Key words

Paraneoplastic neurological syndrome FDG PET MRI Paraneoplastic limbic encephalitis Paraneoplastic cerebellar degeneration 



This work was supported in part by the International Union against Cancer (UICC), Geneva, Switzerland, under the ACSBI fellowship.


  1. 1.
    Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140PubMedCrossRefGoogle Scholar
  2. 2.
    Voltz R (2002) Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis and therapy. Lancet Neurol 1:294–305PubMedCrossRefGoogle Scholar
  3. 3.
    Linke R, Schroeder M, Helmberger T, Voltz R (2004) Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63(2):282–286, Jul 27PubMedGoogle Scholar
  4. 4.
    Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, Vighetto A, Renault-Mannel V, Michel D, Honnorat J (2000) [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 48(1):105–108, JulPubMedCrossRefGoogle Scholar
  5. 5.
    Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, Keir G, Rudge P (2001) The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 124(Pt 11):2223–2231, NovPubMedCrossRefGoogle Scholar
  6. 6.
    Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, Ternamian PJ, Trouillas P, Honnorat J (2004) FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127:2331–2338, OctPubMedCrossRefGoogle Scholar
  7. 7.
    Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J (2005) Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128(Pt 8):1764–1777, AugPubMedCrossRefGoogle Scholar
  8. 8.
    Mathew RM, Cohen AB, Galetta SL, Alavi A, Dalmau J (2006) Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci 250(1–2):153–155, Dec 1PubMedCrossRefGoogle Scholar
  9. 9.
    Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, Maschke M (2005) Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol 252(2):197–201, FebPubMedCrossRefGoogle Scholar
  10. 10.
    Scheid R, Lincke T, Voltz R, von Cramon DY, Sabri O (2004) Serial 18F-fluoro-2-deoxy-d-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol 61(11):1785–1789 Review, NovPubMedCrossRefGoogle Scholar
  11. 11.
    Franck G, Sadzot B, Salmon E et al (1987) Paraneoplastic limbic encephalopathy, inappropriate secretion of ADH, and recurrent infraclinical epileptic seizures: clinical anatomo-pathological and metabolic correlations by positron emission tomography. Rev Neurol (Paris) 143:657–669Google Scholar
  12. 12.
    Fakhoury T, Abou-Khalil B, Kessler RM (1999) Limbic encephalitis and hyperactive foci on PET scan. Seizure 8:427–430PubMedCrossRefGoogle Scholar
  13. 13.
    Provenzale JM, Barboriak DP, Coleman RE (1998) Limbic encephalitis: comparison of FDG PET and MR imaging findings. AJR Am J Roentgenol 170:1659–1660PubMedGoogle Scholar
  14. 14.
    Na DL, Hahm DS, Park JM, Kim SE (2001) Hypermetabolism of the medial temporal lobe in limbic encephalitis on 18FDG-PET scan: a case report. Eur Neurol. 45:187–189PubMedCrossRefGoogle Scholar
  15. 15.
    Kassubek J, Juengling FD, Nitzsche EU, Lücking CH (2001) Limbic encephalitis investigated by 18FDG-PET and 3D MRI. J Neuroimaging 11:55–59PubMedCrossRefGoogle Scholar
  16. 16.
    Lantos PL, Louis DN, Rosenblum MK et al (2002) Paraneoplastic syndromes. In: Graham DI, Lantos PL (eds) Greenfield’s neuropathology. 7th edn. Arnold, London, pp 975–980Google Scholar
  17. 17.
    Rubello D, Vitaliani R, Rigoni MT, Rampin L, Giometto B, Casara D, Zonzin GC, Zavagno G, Capirci C, Shapiro B, Muzzio PC (2005) A rare case of paraneoplastic cerebellar degeneration discovered by whole-body F-18 FDG PET. Clin Nucl Med 30(10):704–706, OctPubMedCrossRefGoogle Scholar
  18. 18.
    Choi KD, Kim JS, Park SH, Kim YK, Kim SE, Smitt PS (2006) Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 77(4):525–528, AprPubMedCrossRefGoogle Scholar
  19. 19.
    Scheid R, Voltz R, Briest S, Kluge R, von Cramon DY (2006) Clinical insights into paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 77(4):529–530, AprPubMedCrossRefGoogle Scholar
  20. 20.
    Leyhe T, Schule R, Schwarzler F, Gasser T, Haarmeier T (2006) Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis. J Neurooncol 78(1):49–51, MayPubMedCrossRefGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2008

Authors and Affiliations

  1. 1.Division of Nuclear MedicineHospital of University of PennsylvaniaPhiladelphiaUSA
  2. 2.Radiation Medicine Centre (BARC)Tata Memorial Hospital AnnexeBombayIndia

Personalised recommendations